EUVIMEDEUVIMED entdecken
Übersichtsarbeit

IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?

Mehmet Kanbay, Sidar Copur, Can Altunbulakli, Zeynep B Eren, Ibrahim Gulmaliyev, Nur I Genc, Caner Süsal, Adrian Covic, Mahmut Altindal

BioDrugs · 2026-11 · 40 (6) · 937-947

DOI: 10.1007/s40259-026-00814-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BioDrugs, online erschienen am 23.10.2026. Verfasst von Mehmet Kanbay und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Koc University School of Medicine, Rumelifeneri YoluSarıyer, 34450, Istanbul, Turkey. mkanbay@ku.edu.…. Hauptthemen laut MEDLINE: Graft Rejection, Kidney Transplantation, Antibodies, Monoclonal, Humanized, Interleukin-6 Inhibitors. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two of the most significant challenges in transplantation medicine are human leukocyte antigen sensitization, which limits access to kidney transplantation for patients with end-stage kidney disease owing to the lack of effective desensitization strategies, and chronic active antibody-mediated rejection (cAMR), a major cause of allograft dysfunction and graft loss following transplantation. Despite its substantial clinical significance, there remains a lack of high-quality evidence and well-established therapeutic algorithms for the management of cAMR, while many patients continue to be excluded from kidney transplantation because of immunological barriers. Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a central role in both innate and adaptive immune responses. Beyond its immunological functions, IL-6 has been implicated in the pathogenesis of a wide range of conditions, including atherosclerotic cardiovascular disease, diabetes mellitus, and various neurological disorders. Consequently, targeting the IL-6/IL-6 receptor signaling pathway has emerged as a promising therapeutic strategy in transplantation medicine, particularly for desensitization protocols and the treatment of cAMR. However, the current evidence base is restricted to studies evaluating tocilizumab and clazakizumab, with clinical benefits remaining inconsistent across studies. Limited evidence is available regarding the desensitization effectiveness of tocilizumab monotherapy. In cAMR, the phase III IMAGINE trial found no improvement in kidney function with clazakizumab despite reduced C-reactive protein. Current evidence does not support a routine IL-6 pathway blockade in cAMR, while further studies are required to prove the potential benefits in desensitization. In this narrative review, we comprehensively examine the role of IL-6 in the pathophysiology of kidney transplantation and critically appraise the available clinical evidence regarding IL-6/IL-6R-targeted therapies for the management of human leukocyte antigen sensitization and cAMR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft RejectionKidney TransplantationAntibodies, Monoclonal, HumanizedInterleukin-6 InhibitorsHumansInterleukin-6Receptors, Interleukin-6AnimalsSignal Transduction

Substanzen

Antibodies, Monoclonal, HumanizedInterleukin-6tocilizumabInterleukin-6 InhibitorsReceptors, Interleukin-6clazakizumab

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Koc University School of Medicine, Rumelifeneri YoluSarıyer, 34450, Istanbul, Turkey. mkanbay@ku.edu.tr.
  • Munci Kalayoglu Organ Transplant Center, Koc University Hospital, Istanbul, Turkey. mkanbay@ku.edu.tr.
  • Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
  • School of Medicine, Koç University, Istanbul, Turkey.
  • Transplant Immunology Research Center of Excellence TIREX, Koç University, Istanbul, Turkey.
  • Department of Nephrology, "Grigore T. Popa" University of Medicine and Pharmacy, 700115, Iași, Romania.

Zitieren

APA

Kanbay, M., Copur, S., Altunbulakli, C., Eren, Z. B., Gulmaliyev, I., Genc, N. I., Süsal, C., Covic, A., & Altindal, M. (2026). IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?. BioDrugs, 40(6), 937-947. https://doi.org/10.1007/s40259-026-00814-9

Vancouver

Kanbay M, Copur S, Altunbulakli C, Eren ZB, Gulmaliyev I, Genc NI, et al. IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?. BioDrugs. 2026;40(6):937-947. doi:10.1007/s40259-026-00814-9

BibTeX
@article{Kanbay2026,
  author = {Kanbay, Mehmet and Copur, Sidar and Altunbulakli, Can and Eren, Zeynep B and Gulmaliyev, Ibrahim and Genc, Nur I and Süsal, Caner and Covic, Adrian and Altindal, Mahmut},
  title = {IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?},
  journal = {BioDrugs},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {937--947},
  doi = {10.1007/s40259-026-00814-9}
}
Kostenlos starten →